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Purpose: To describe the effect of rituximab on full-ﬁeld electroretinography (ERG) in a patient with
nonparaneoplastic autoimmune retinopathy (npAIR).
Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
negative work-up for cancer was diagnosed with npAIR. Visual acuity and ancillary tests were normal
except abnormal ERG in both eyes. The patient was given one course of rituximab 375 mg/m2/week for 4
weeks and cyclophosphamide 1 gr/m2/month for 6 months. A second course of rituximab was necessary
as autoantibody titers showed no change and as new antibodies were noted after treatment with rit-
uximab and cyclophosphamide. Electroretinography was repeated after the ﬁrst course of rituximab,
after cyclophosphamide, and the second course of rituximab therapy.
Conclusions and importance: Rituximab therapy led to marked improvement in full-ﬁeld ERG readings
and regression of symptoms was reported by the patient after rituximab infusions. The effect of ritux-
imab in npAIR was objectively demonstrated with ERG.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autoimmune retinopathy (AIR) is an immune-mediated retinal
degeneration characterized by progressive vision loss, abnormal
electroretinography (ERG), visual ﬁeld deﬁcits, and presence of
circulating anti-retinal autoantibodies. Two forms of AIR exists:
paraneoplastic (pAIR) and nonparaneoplastic (npAIR). Paraneo-
plastic AIR is further subdivided into cancer-associated retinopathy
(CAR) and melanoma-associated retinopathy (MAR) [1e5]. Lym-
phoma associated retinopathy (LAR) has also been described [6e8].
Nonparaneoplastic AIR is more common than pAIR [1,3,4]. Patients
with npAIR are mostly female and have a history and/or family
history of autoimmune disease [1e4].si Hastanesi, Goz Hastaliklari
Istanbul, Turkey.
.
Inc. This is an open access article uThe diagnosis of AIR should be considered in patients with
subacute vision loss, photopsias, nyctalopia, scotomas, photo-
aversion, dyschromatopsia and/or visual ﬁeld loss [1e5]. Some
patients may also have diminished central vision and loss of
contrast sensitivity [4]. Symptoms are usually bilateral, but can be
asymmetric between the eyes [1e5]. Visual acuity may be deceiv-
ingly good in the early stages of the disease [1]. The fundus can
appear unremarkable initially and demonstrate retinal vascular
attenuation, diffuse retinal atrophy, retinal pigment epithelium
abnormalities, and/or disc pallor later in the disease course [1e5].
Usually, there is no or minimal intraocular inﬂammation [1e5]. The
mean age of onset ranges between 55 and 65 years, with npAIR
having a younger age of onset than pAIR [2].
Because of the presumed autoimmune nature of AIRs immu-
nomodulatory agents have been used in an attempt to treat the
disease. It is uncertain whether treatment signiﬁcantly alters the
natural course of the disease [1]. More favorable treatment results
are achieved in pAIR, particularly CAR [1]. An early attempt to treat
AIRs is suggested to end-up with a beneﬁcial outcome [1,9].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Color fundus photograph of the right (A) and left eye (B) show attenuated
retinal vessels more prominent in the retinal arteries than in retinal veins. Fluorescein
angiography shows no abnormal ﬂuorescence in the early (C, D) and late frames (E, F)
G. Uludag et al. / American Journal of Ophthalmology Case Reports 2 (2016) 4e7 52. Case report
A 58-year-old male patient was referred to the oncology
department in August 2014 with a preliminary diagnosis of CAR
due to abnormal full-ﬁeld ERG and elevated cancer antigen (CA) 15-
3. The patient was complaining of seeing a peripheral white halo
when passing from dark to light and vision fading of colors more
prominent in his right eye, for 5 months. He had systemic hyper-
tension and liver hemangiomas. He denied smoking and family
history of cancer and autoimmune disease.
Work-up revealed microangiopathic gliosis on cranial magnetic
resonance imaging (MRI), hepatic hemangiomas on abdominal MRI
(stable when compared with the abdominal MRI taken in 2012),
and a normal esophagogastroduedenoscopy and colonoscopy.
Complete blood count, serum biochemistry, free/total prostate
speciﬁc antigen, CA 19-9, carcinoembriogenic antigen, and alpha-
fetoprotein were normal. Repeat CA15-3 was positive at 30.4 U/
mL (normal: 0e25 U/mL). Ultrasound of subareolar breast tissue
was normal. Positron emission tomography/computed tomography
showed no hypermetabolic activity.
Ophthalmologic examination showed a best-corrected visual
acuity of 1.0 in both eyes. Pupils were equal and reactive to light;
there was no relative afferent pupillary defect. Biomicroscopy was
unremarkable in both eyes. Intraocular pressures were 16 mmHg in
both eyes. Fundus examination showed attenuated retinal vessels
more prominent in the retinal arteries than in retinal veins bilat-
erally (Fig. 1A, B). Fluorescein angiography, fundus auto-
ﬂuorescence, spectral-domain optical coherence tomography (SD
OCT), and computerized perimetry were normal in both eyes
(Fig. 1CeL). Full-ﬁeld ERG and pattern visual evoked potentials
(VEP) and ERG were conducted in October 2014 (Table 1). Western
blot analyses at Casey Eye Institute Ocular Immunology Laboratory
showed anti-retinal autoantibodies against 23-kDa (not reactive to
recoverin), 42-kDa, and 70-kDa proteins and anti-optic nerve
autoantibody against 35-kDa protein. A diagnosis of npAIR was
established based on the patient's visual symptoms, abnormal full-
ﬁeld ERG, and the presence of anti-retinal autoantibodies. A treat-
ment protocol consisting of 4 cycles of rituximab 375 mg/m2/week,
followed by 6 cycles of cyclophosphamide 1 gr/m2/month was
planed. Electroretinography was repeated after 4 cycles of ritux-
imab infusions before cyclophosphamidewas begun and after the 6
cycles of cyclophosphamide therapy. Despite remaining subnormal
amarked improvement in full-ﬁeld ERG parameters was recorded 3
weeks after the course of rituximab and before cyclophosphamide
treatment in February 2015 (Table 1). The patient reported recovery
in visual symptoms after the third cycle of rituximab infusion.
After completion of 6 cycles of intravenous pulse cyclophos-
phamide therapy full-ﬁeld ERG was repeated in August 2015
(Table 1) and blood was send to Casey Eye Institute Ocular Immu-
nology Laboratory for re-evaluation. Although full-ﬁeld ERG read-
ings showed a decline when compared to post-rituximab, readings
were still better than baseline. Anti-retinal antibody testing
showed positivity of 23-kDa (not reactive to recoverin), 36-kDa
(GADPH), 40-kDa (aldolase), and 42-kDa with no signiﬁcant
change in previous antibody titers and presence of new auto-
antibodies. Also were noted new anti-optic nerve antibodies
against 19-kDa, 21-kDa, 23-kDa, 35-kDa and 136-kDa proteins.in the right and left eye. Fundus autoﬂuorescence shows normal autoﬂuorescence in
the right (G) and left eye (H). Spectral-domain optical coherence tomography of the
right (I) and left eye (J) shows normal inner and outer retinal architecture. Pattern
deviation plot of visual ﬁeld testing with 30-2 Swedish Interactive Thresholding Al-
gorithm (SITA) Fast program of the Humphrey Field Analyzer is within normal limits in
the right (K) and left eye (L).
Table 1
Electrophysiological test readings of the patient at baseline and following each immunomodulatory agent given.
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second course of 4 cycles of rituximab therapy (375 mg/m2/week).
Post-therapy ERG in December 2015 showed a marked improve-
ment in ERG with the most prominent changes occurring in dark
adapted 3.0 a- and b-waves showing combined rod-cone response
and oscillatory potentials indicating inner retinal function (Table 1).
The patient reported recovery in visual symptoms after the second
course of rituximab as well. A third blood sample obtained after the
second course of rituximab therapy showed positive anti-retinal
autoantibodies against 23-kDa (not reactive to recoverin), 40-kDa
(aldolase), 42-kDa, and 62-kDa proteins and anti-optic nerve au-
toantibodies against 21-kDa, 23-kDa, 30-kDa, 40-kDa, and 136-kDa
proteins. The laboratory reported no signiﬁcant change since the
last testing.
The patient's complete blood count was followed along treat-
ment. Lymphocyte count was 2500/mL (normal range: 1000e7000/
mL) at baseline and decreased to 1800/mL immediately after the 4th
cycle of rituximab before cyclophosphamide was begun, 1100/mL
after completion of cyclophosphamide therapy before the second
course of rituximab and remained at 1100/mL immediately after the
4th cycle of second course of rituximab.
The patient was re-surveyed for cancer development in August
2015 and PET/CT was negative for malignancy. Cancer antigen 15-3
was re-detected at 31.6 U/mL (normal: 0e25 U/mL). Regular
ophthalmological follow-up examinations were stable and repeat
SD OCT and computerized perimetry remained normal.
This report was deemed exempt from institutional review board
approval and an informed consent was obtained from the patient.3. Discussion
Treatment options for AIRs are systemic and local corticoste-
roids, plasmapheresis, intravenous immunoglobulin, and conven-
tional immunomodulatory therapy with azathioprine,
mycophenolate mofetil, and cyclosporine A [1e5,9]. Rituximab is a
monoclonal antibody against CD20 expressed on B cells and was
originally developed for the treatment of non-Hodgkin's B-cell
lymphoma. In the last several years B-cell targeting therapies were
approved for the treatment of autoimmune diseases. Rituximab
depletes B-cells by antibody and complement-dependent cytotox-
icity and stimulation of apoptotic pathways. The cell surface
glycoprotein CD20 is expressed on B-cells from early development
in the bone marrow until terminal differentiation to plasma cells.
Therefore, rituximab depletes immature and mature B-cells from
blood and tissue and does not eliminate long-lived plasma cells that
are the main source of antibodies [10]. Presence of anti-retinal
antibodies and an abnormal ERG is crucial in establishing the
diagnosis of AIRs [1e5]. Rituximab treatment effectively stabilized
or improved visual acuity in three separate case reports on AIR
[11e13]. In only one of the reports serum testing was repeated after
rituximab therapy and showed a decline in the immunoreactivity
against human retina by indirect immunohistochemistry [11]. In
the remaining two reports repeat serum testing to assess for a
change in anti-retinal antibodies following rituximab therapy was
not studied. Serum anti-retinal and anti-optic nerve antibodies did
not decline and there was even occurrence of new antibodies in the
post-therapy serum samples of the patient reported herein who
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role electroretinography is also used as an indicator for treatment
response [1,4,9]. Post-therapy ERG has not been done in the rit-
uximab treated AIR cases [11e13]. In our case full-ﬁeld ERG re-
sponses showedmarked improvement after the 1st and 2nd course
of rituximab therapy given as 4 cycles at a dose of 375mg/m2/week.
There was also recovery in the patient's symptoms reported to
occur immediately after the rituximab infusions. Although wewere
able to document a marked improvement of full-ﬁeld ERG after
rituximab infusions, we could not demonstrate a decline or nega-
tivity of auto-antibodies following treatment with rituximab. We
speculate that it might be related to the persistence of plasma cells
despite presence of rituximab induced altered humoral immunity.
Although a decrease or negativity of auto-antibodies following
treatment with other immunomodulatory agents has been re-
ported, the signiﬁcance of this ﬁnding is unclear as anti-retinal
antibodies have a broad range of speciﬁcity and heterogeneity
and as the pathogenic mechanisms of retinopathies are complex
[1,14].
Non-paraneoplastic AIR with presence of retinal and optic nerve
autoantibodies is called autoimmune-related retinopathy and optic
neuropathy (ARRON) [15,16]. Despite lack of optic disc staining in
ﬂuorescein angiography and visual ﬁeld defect(s) that would indi-
cate optic nerve involvement, our patient had positive anti-optic
nerve antibody initially and the presence of new anti-optic nerve
antibodies were noted in the second and third blood samples. A
worsening in pattern VEP and ERG (N95 latency signifying ganglion
cell function) was observed after the ﬁrst course of rituximab. There
is no report on VEP and pattern ERG in ARRON. Despite presence of
new anti-optic nerve antibodies, an abnormality did not occur in
follow-up pattern VEP examinations and an abnormal reading was
only documented in the worse right eye of the patient at the ﬁnal
electrophysiological evaluation in December 2015. We hypothesize
that optic nerve function may not improve after therapy in ARRON
as seen in demyelinating optic neuropathies [17].
Although recoverin, a 23-kDa calcium-binding protein found
on photoreceptors, and a-enolase, a-46 kDa ubiquitous glycolytic
enzyme, are the most widely studied antigens in AIR, other au-
toantibodies including those against carbonic anhydrase, arrestin,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldolase,
transducing-b, TULP1, neuroﬁlament protein, heat shock protein-
70, photoreceptor-cell-speciﬁc nuclear receptor, Müller-cell-spe-
ciﬁc antigen, transient receptor potential cation channel, sub-
family M, member 1 (TRPM1), and a number of antigens that are
still unidentiﬁed were studied [2]. Most patients with AIR symp-
toms and signs have multiple bands of anti-retinal antibodies on
Western blot with the majority showing a minimum of three
different bands as in our case [4]. In our patient the diagnosis of
npAIR was established based on positive anti-retinal antibodies on
Western blot against 23-kDa, 42-kDa, and 70-kDa proteins. The
23-kDa protein did not correspond to anti-recoverin antibody.
Although recoverin has been historically shown to be a target
antigen in CAR the incidence of anti-recoverin antibodies in CAR isvery low across different kinds of tumor and ranges between 3%
and 5% [18].
Despite a positive CA15-3, which is not a sensitive tumormarker
per se, the patient's work-up revealed no cancer [19]. However, the
patient remains as a suspect for CAR, as the patient is 58-year-old,
of male gender, has no history and/or family history of autoimmune
disease, and as autoantibodies may precede cancer development in
pAIR. Continued surveillance for malignancy appears mandatory in
the follow-up of the patient. The patient reported herein represents
electroretinographic evidence for the successful treatment of AIR
with rituximab.
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